PMID- 33585034
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210216
IS  - 2049-9434 (Print)
IS  - 2049-9442 (Electronic)
IS  - 2049-9434 (Linking)
VI  - 14
IP  - 3
DP  - 2021 Mar
TI  - Long-term vonoprazan therapy is effective for controlling symptomatic proton pump 
      inhibitor-resistant gastroesophageal reflux disease.
PG  - 32
LID - 10.3892/br.2021.1408 [doi]
LID - 32
AB  - Vonoprazan, a novel potassium-competitive acid blocker, results in greater 
      inhibition of gastric acid secretion than proton pump inhibitors (PPI). The aim 
      of this study was to assess the long-term outcomes of patients with PPI-resistant 
      gastroesophageal reflux disease (GERD) treated with vonoprazan. The medical 
      records of patients with symptomatic GERD treated with vonoprazan for 1 year were 
      retrospectively reviewed. Changes in abdominal symptoms were assessed using the 
      Izumo scale, a self-reported questionnaire which is useful in evaluating the 
      symptoms of GERD, epigastric pain, postprandial distress, constipation and 
      diarrhea, and is commonly used in routine clinical practice. A total of 30 
      patients were included and stratified into a non-erosive (n=22) and erosive group 
      (n=8). At baseline, postprandial distress symptoms were significantly greater in 
      the non-erosive group compared with the erosive group (P=0.013). Even with 
      vonoprazan therapy, symptoms of GERD in the non-erosive group were refractory 
      compared with the erosive group, and required additional treatment in a larger 
      proportion of patients (45 vs. 13%). GERD symptoms in the non-erosive group 
      significantly improved from baseline and remained better after 1 year of 
      vonoprazan therapy, similar to the erosive group. In addition, vonoprazan 
      improved epigastric pain and postprandial distress symptoms in the non-erosive 
      group, and 1 year of vonoprazan therapy did not aggravate constipation or 
      diarrhea. In conclusion, 1 year of vonoprazan therapy improves GERD symptoms in 
      patients with PPI-resistant GERD.
CI  - Copyright (c) 2020, Spandidos Publications.
FAU - Shinozaki, Satoshi
AU  - Shinozaki S
AD  - Shinozaki Medical Clinic, Utsunomiya, Tochigi 321-3223, Japan.
AD  - Department of Medicine, Division of Gastroenterology, Jichi Medical University, 
      Shimotsuke, Tochigi 329-0498, Japan.
FAU - Osawa, Hiroyuki
AU  - Osawa H
AD  - Department of Medicine, Division of Gastroenterology, Jichi Medical University, 
      Shimotsuke, Tochigi 329-0498, Japan.
FAU - Hayashi, Yoshikazu
AU  - Hayashi Y
AD  - Department of Medicine, Division of Gastroenterology, Jichi Medical University, 
      Shimotsuke, Tochigi 329-0498, Japan.
FAU - Miura, Yoshimasa
AU  - Miura Y
AD  - Department of Medicine, Division of Gastroenterology, Jichi Medical University, 
      Shimotsuke, Tochigi 329-0498, Japan.
FAU - Lefor, Alan Kawarai
AU  - Lefor AK
AD  - Department of Surgery, Jichi Medical University, Shimotsuke, Tochigi 329-0498, 
      Japan.
FAU - Yamamoto, Hironori
AU  - Yamamoto H
AD  - Department of Medicine, Division of Gastroenterology, Jichi Medical University, 
      Shimotsuke, Tochigi 329-0498, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210201
PL  - England
TA  - Biomed Rep
JT  - Biomedical reports
JID - 101613227
PMC - PMC7873583
OTO - NOTNLM
OT  - GERD
OT  - PPI
OT  - dyspepsia
OT  - potassium-competitive acid blocker
OT  - therapeutic outcome
EDAT- 2021/02/16 06:00
MHDA- 2021/02/16 06:01
PMCR- 2021/02/01
CRDT- 2021/02/15 06:09
PHST- 2020/11/14 00:00 [received]
PHST- 2021/01/19 00:00 [accepted]
PHST- 2021/02/15 06:09 [entrez]
PHST- 2021/02/16 06:00 [pubmed]
PHST- 2021/02/16 06:01 [medline]
PHST- 2021/02/01 00:00 [pmc-release]
AID - BR-0-0-01408 [pii]
AID - 10.3892/br.2021.1408 [doi]
PST - ppublish
SO  - Biomed Rep. 2021 Mar;14(3):32. doi: 10.3892/br.2021.1408. Epub 2021 Feb 1.